Artigos de revistas: "Instent restenosis"

1

Praveen Kumar, M., S. Suresh Kumar e T. Munusamy. "INSTENT RESTENOSIS WITH BIFURCATION STENTING". Indian Heart Journal 75 (dezembro de 2023): S60. http://dx.doi.org/10.1016/j.ihj.2023.11.126.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

2

Chen, Yin, Shilian Hu e Lei Wu. "Drug-eluting balloon for instent restenosis". Heart 99, n.º 24 (16 de agosto de 2013): 1874.1–1874. http://dx.doi.org/10.1136/heartjnl-2013-304720.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

3

Bahl, Rahul, Andreas Indermuehle, Georg M. Froehlich, Alexandra J. Lansky, Guido Knapp, Adam Timmis e Pascal Meier. "Drug-eluting balloon for instent restenosis". Heart 99, n.º 24 (19 de agosto de 2013): 1874.2–1875. http://dx.doi.org/10.1136/heartjnl-2013-304722.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

4

Gonzalez, Alberto J., Michael A. Drummond, R. Scott McCord e H. Edward Garrett. "Carotid Endarterectomy for Treatment of Instent Restenosis". Journal of Vascular Surgery 52, n.º 6 (dezembro de 2010): 1742. http://dx.doi.org/10.1016/j.jvs.2010.10.025.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

5

Exner, Markus, Schila Sabet, Wolfgang Mlekusch, Jasmin Amighi, Sylvia Handler, Peter Quehenberger, Neda Kalifeh, Oswald Wagner, Erich Minar e Martin Schillinger. "High plasma heparin cofactor II activity protects from restenosis after femoropopliteal stenting". Thrombosis and Haemostasis 92, n.º 11 (2004): 1108–13. http://dx.doi.org/10.1160/th04-05-0311.

Texto completo da fonte

Resumo:

SummaryHigh heparin cofactor II (HCII) activity has recently been described to protect from coronary instent restenosis, presumably by inactivating thrombin in injured arteries. In this study, we investigated the association of HCII activity and restenosis after femoropopliteal stenting. We studied 63 consecutive patients with peripheral artery disease who underwent femoropopliteal stent implantation after initial failure of plain balloon angioplasty due to a significant residual stenosis (>30% lumen diameter reduction) or a flow limiting dissection. HCII activity was measured before stenting and patients were followed for median 10 months (interquartile range 6 to 17) for the occurrence of a first instent restenosis, defined as a >50% lumen diameter reduction by color coded duplex sonography and confirmed by angiography. Cumulative freedom from restenosis at 6 and 12 months in patients with lower HCII activity (≤100%, lower tertile, n=20) was 84% and 35% as compared to 93% and 72% in patients with high HCII activity (>100%, middle and upper tertile, n=43; p=0.024 by Log Rank test). Adjusting for the material of the implanted stents (nitinol vs.Wallstents), patients with a high HCII activity had a 0.39-fold reduced risk for instent restenosis (95% CI 0.17 to 0.90, p=0.028), additional adjustment for diabetes mellitus, poor run-off, critical limb ischemia and cumulative length of the stented segment did not alter the observed effect. Higher activity of heparin cofactor II may exert a protective effect against instent restenosis also in the femoropopliteal vessel area, confirming a prior observation after coronary stenting.

Estilos ABNT, Harvard, Vancouver, APA, etc.

6

Dussaillant, Gaston R., Gary S. Mintz, Augusto D. Pichard, Kenneth M. Kent, Lowell F. Satler, Jeffrey J. Popma, Paul Mackel et al. "A serial volumetricintravascular ultrasound analysis of instent restenosis". Journal of the American College of Cardiology 27, n.º 2 (fevereiro de 1996): 362. http://dx.doi.org/10.1016/s0735-1097(96)82365-5.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

7

Şabanoğlu, Cengiz, Esra Polat e Elif İlkay Yüce. "The Association Between Coronary Instent Restenosis and Eosinophil/Monocyte Ratio". e-Journal of Cardiovascular Medicine 10, n.º 3 (1 de setembro de 2022): 137–43. http://dx.doi.org/10.32596/ejcm.galenos.2022.2022-08-045.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

8

Akin, E., K. Knobloch, M. Pichlmaier e A. Haverich. "Instent restenosis after carotid stenting necessitating open carotid surgical repair". European Journal of Cardio-Thoracic Surgery 26, n.º 2 (agosto de 2004): 442–43. http://dx.doi.org/10.1016/j.ejcts.2004.03.047.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

9

Tilara, Mandip, Rakesh Tirmale e Sharad Jain. "Study of clinico-etiological profile of patients with instent restenosis". Indian Heart Journal 69 (novembro de 2017): S62. http://dx.doi.org/10.1016/j.ihj.2017.09.181.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

10

Judkins, C., A. Wilson e P. Barlis. "A Presentation on Lipid and Protein Markers of Instent Restenosis". Heart, Lung and Circulation 25 (agosto de 2016): S163. http://dx.doi.org/10.1016/j.hlc.2016.06.384.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

11

Zeller, Thomas, Aljoscha Rastan, Uwe Schwarzwälder, Christian Mueller, Thomas Schwarz, Ulrich Frank, Karlheinz Bürgelin et al. "Treatment of instent restenosis following stent-supported renal artery angioplasty". Catheterization and Cardiovascular Interventions 70, n.º 3 (2007): 454–59. http://dx.doi.org/10.1002/ccd.21220.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

12

Hassid, Babak, Arber Kodra, Michael C. Kim, Rajiv Sharma, Seth Blacksburg, Potters Louis e Varinder P. Singh. "SAFETY AND EFFICACY OF INTRACORONARY BRACHYTHERAPY PROTOCOL FOR RESISTANT INSTENT RESTENOSIS". Journal of the American College of Cardiology 79, n.º 9 (março de 2022): 849. http://dx.doi.org/10.1016/s0735-1097(22)01840-x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

13

Mastuda, Junji, Taishi Yonetsu, Tadashi Murai, Yoshihisa Kanaji, Eisuke Usui, Makoto Araki, Takayuki Niida, Rikuta Hamaya e Tsunekazu Kakuta. "COMPARISON BETWEEN ANGIOSCOPIC AND OPTICAL COHERENCE TOMOGRAPHIC ASSESSMENT OF INSTENT RESTENOSIS". Journal of the American College of Cardiology 69, n.º 11 (março de 2017): 298. http://dx.doi.org/10.1016/s0735-1097(17)33687-2.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

14

Shah, J., M. Sebastian, N. Andrianopoulos, D. Clark, B. Yan, A. Brennan, C. Jaworski et al. "How should we treat drug eluting stent (DES) instent restenosis (ISR)?" Heart, Lung and Circulation 24 (2015): S277. http://dx.doi.org/10.1016/j.hlc.2015.06.389.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

15

Engel, L., R. Adolf, I. Kringe, S. Cassese, A. Kastrati, M. Joner, H. Schunkert, A. Will e M. Hadamitzky. "Identification Of Morphologic And Inflammatory Predictors Of Instent-Restenosis Using CCTA". Journal of Cardiovascular Computed Tomography 17, n.º 4 (julho de 2023): S18. http://dx.doi.org/10.1016/j.jcct.2023.05.050.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

16

Jayaraj, Arjun, Robert Fuller e Seshadri Raju. "Role of laser ablation in recalcitrant instent restenosis post iliofemoral venous stenting". Journal of Vascular Surgery Cases, Innovations and Techniques 7, n.º 2 (junho de 2021): 298–301. http://dx.doi.org/10.1016/j.jvscit.2021.03.004.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

17

Amritphale, Amod. "Are Biodegradable Third Generation Drug Eluting Stents the Answer to Instent Restenosis?" Cardiology and Angiology: An International Journal 2, n.º 1 (10 de janeiro de 2014): 15–40. http://dx.doi.org/10.9734/ca/2014/9138.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

18

Mews, Geoffrey C., Geoffrey D. Cope, Richard A. Fox, Richard A. Clugston, James M. Rankin, Neil Cumpston, Mark Horrigan e Anthony W. Rafter. "A random placebo controlled trial of intracoronary RHENIUM-188 for instent restenosis". Heart, Lung and Circulation 12, n.º 2 (janeiro de 2003): A97—A98. http://dx.doi.org/10.1046/j.1443-9506.2003.03672.x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

19

Lee, Wei-Chieh. "TCT-406 The Predictors of Instent Restenosis Again After Drug Eluting Balloon". Journal of the American College of Cardiology 66, n.º 15 (outubro de 2015): B164—B165. http://dx.doi.org/10.1016/j.jacc.2015.08.420.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

20

Schillinger, Martin. "How to treat recurrent renal artery instent restenosis? Editorial comment on treatment of reoccuring instent restenosis following reintervention after stent-supported renal artery angioplasty–Article by Zeller et al." Catheterization and Cardiovascular Interventions 70, n.º 2 (2007): 301–2. http://dx.doi.org/10.1002/ccd.21294.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

21

Timizheva, K. B., A. V. Aghajanyan, L. V. Tskhovrebova, Z. Kh Shugushev e M. M. Azova. "Assessment of the role of IL6 and IL10 gene polymorphisms as a risk factor for the development of restenosis in patients after implantation of drug-eluting stents". RUDN Journal of Medicine 25, n.º 1 (15 de dezembro de 2021): 48–54. http://dx.doi.org/10.22363/2313-0245-2021-25-1-48-54.

Texto completo da fonte

Resumo:

Relevance. Currently, the number of percutaneous coronary interventions continues to increase, which leads to an increase in the absolute number of restenosis cases, which is the main complication of the long-term postoperative period. The search for risk factors responsible for restenosis and artery re-narrowing mechanisms in order to prevent this complication is an important goal in interventional cardiology. Risk factors for the restenosis development include clinical, angiographic and genetic factors. An active search for biomolecular markers associated with the coronary artery restenosis is currently underway. Objective: to study the role of polymorphic variants C-174G of the IL6 gene and C-819T of the IL10 gene as a risk factor for the development of restenosis in patients after stent implantation. Materials and Methods : The study included 113 patients with stable coronary artery disease, who had previously undergone balloon angioplasty and implantation of drug-eluting stents, and 62 patients with intact arteries that were included to the control group. Statistical data processing was carried out using the R-language program and the SPSS Statistics 20 software package. Results: GG genotype for IL6 gene was associated with the development of coronary artery disease. In the subgroup of patients over 65 years of age and instent restenosis, the GG genotype was significantly less frequent. The homozygous CC genotype for IL10 gene was associated with rapid angiographic in-stent restenosis progression.

Estilos ABNT, Harvard, Vancouver, APA, etc.

22

Kaplan, Sahin, Peter Barlis, Jun Tanigawa, Omer Goktekin e Carlo Di Mario. "Unconventional treatment of aorto-ostial instent restenosis with marked protrusion into the aorta". Journal of Cardiovascular Medicine 9, n.º 2 (fevereiro de 2008): 184–86. http://dx.doi.org/10.2459/jcm.0b013e3280126208.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

23

Jensen, L. O., P. Thayssen, J. F. Lassen, H. S. Hansen, H. Kelbaek, A. Junker, K. E. Pedersen et al. "Recruitable collateral blood flow index predicts coronary instent restenosis after percutaneous coronary intervention". European Heart Journal 28, n.º 15 (31 de maio de 2007): 1820–26. http://dx.doi.org/10.1093/eurheartj/ehm067.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

24

Mehran, Roxana, Gary S. Mintz, Jeffrey J. Popma, Augusto D. Pichard, Lowell F. Satler, Kenneth M. Kent, S. Chiu Wong e Martin B. Leon. "Excimer laser angioplasty in the treatment of instent restenosis: An intravascular ultrasound study". Journal of the American College of Cardiology 27, n.º 2 (fevereiro de 1996): 362. http://dx.doi.org/10.1016/s0735-1097(96)82364-3.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

25

Ghoshal, A., e A. Mishra. "Outcomes of drug eluting balloon in native coronaries & venous graft instent restenosis". Heart, Lung and Circulation 24 (2015): S158. http://dx.doi.org/10.1016/j.hlc.2015.06.108.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

26

Zeller, Thomas, Sebastian Sixt, Aljoscha Rastan, Uwe Schwarzwälder, Christian Müller, Ulrich Frank, Karlheinz Bürgelin et al. "Treatment of reoccurring instent restenosis following reintervention after stent-supported renal artery angioplasty". Catheterization and Cardiovascular Interventions 70, n.º 2 (2007): 296–300. http://dx.doi.org/10.1002/ccd.21170.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

27

Böhme, Tanja, Elias Noory, Ulrich Beschorner, Frederik Lerke, Andrej Schmidt, Dierk Scheinert, Wulf Ito, Thomas Zeller e Aljoscha Rastan. "Photoablative atherectomy followed by a paclitaxel-coated balloon to inhibit restenosis in instent femoro-popliteal obstructions (PHOTOPAC)". Vasa 50, n.º 5 (setembro de 2021): 387–93. http://dx.doi.org/10.1024/0301-1526/a000959.

Texto completo da fonte

Resumo:

Summary: Background: To evaluate the safety and effectiveness of preparing instent femoropopliteal lesion with photoablative laser atherectomy or plain balloon angioplasty (POBA) prior to drug-coated balloon (DCB) angioplasty. Patients and methods: The prospective, multicenter, randomized study enrolled patients with Rutherford-Becker-class (RBC) 1 to 5 and instent lesions located in superficial femoral artery and/or popliteal artery above the knee joint. Primary endpoint was target lesion percent stenosis at 1 year as determined by the angiographic core-laboratory. Secondary endpoints included procedural success, major adverse event rate, clinical improvement and improvement in ankle-brachial index (ABI), clinically-driven target lesion revascularization (CD-TLR), and primary patency rate at until 2-year follow-up. Results: The study was terminated prior to the enrollment goal due to slow enrollment. Thirty patients were included in the laser plus DCB cohort and 31 patients in the control cohort. Primary endpoint was not significantly different (p=0.331). Procedural success was 83.3% and 87.1% for the laser plus DCB and the control cohort, respectively. Serious adverse events at 30 days and 1-year were not statistically different between the two cohorts. For the ABI, significant improvements were present at discharge as well as at the follow-up visits. This was also evident for the RBC at the follow-up visits. One- and two-year freedom from CD-TLR was 86.7% vs. 87.1%, and 63.6% vs. 72%, respectively. Duplex derived primary patency was 90% at 6-months, 65.5% at one year and 56.5% at two year for the laser cohort and 90.3%, 75.9% and 53.8% for the control cohort. Conclusions: Safety of instent photoablative laser atherectomy followed by DCB angioplasty is confirmed by this study. Due to the small sample size, no benefit over POBA as vessel preparation could be shown.

Estilos ABNT, Harvard, Vancouver, APA, etc.

28

Sakai, Hidetsugu, Naotsugu Oyama, Noriaki Kishimoto, Masashige Takahashi, Kazushi Urasawa e Hiroyuki Tsutsui. "Revascularization of Malignant Coronary Instent Restenosis Resulting From Takayasu's Arteritis Using Sirolimus-Eluting Stents". International Heart Journal 47, n.º 5 (2006): 795–801. http://dx.doi.org/10.1536/ihj.47.795.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

29

Xu, Jack, Michael S. Cross, Swetal Patel e Subhi Jamal Alaref. "UTILIZING SHOCKWAVE THERAPY FOR THE TREATMENT OF RECURRENT INSTENT RESTENOSIS AND SIGNIFICANT CORONARY CALCIFICATION". Journal of the American College of Cardiology 79, n.º 9 (março de 2022): 2284. http://dx.doi.org/10.1016/s0735-1097(22)03275-2.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

30

Taniwaki, Masanori, Keiichi Onishi, Hirotaka Ezaki, Yoshio Maeno, Tomohisa Saitoh, Takayuki Miyake e Masami Sakurada. "PERFORMANCE OF ULTRA-HIGH RESOLUTION CT OF INSTENT RESTENOSIS OF BELOW 3.0MM CORONARY STENT". Journal of the American College of Cardiology 75, n.º 11 (março de 2020): 1629. http://dx.doi.org/10.1016/s0735-1097(20)32256-7.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

31

Mahdi, N. "PTCA, Directional and Rotational Coronary Atherectomy in the Management of Palmaz-Schatz Instent Restenosis". Journal of the American College of Cardiology 31, n.º 2 (fevereiro de 1998): 275A. http://dx.doi.org/10.1016/s0735-1097(97)84905-4.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

32

Swinnen, Jan “John”, Kerry Hitos, Lukas Kairaitis, Simon Gruenewald, George Larcos, David Farlow, David Huber et al. "Multicentre, randomised, blinded, control trial of drug-eluting balloon vs Sham in recurrent native dialysis fistula stenoses". Journal of Vascular Access 20, n.º 3 (18 de setembro de 2018): 260–69. http://dx.doi.org/10.1177/1129729818801556.

Texto completo da fonte

Resumo:

Background: Endovascular treatment of autogenous arteriovenous haemodialysis fistula stenosis has high reintervention rates. We investigate the effect of drug-eluting balloons in the treatment of recurrent haemodialysis fistula stenosis. Methods: This is a randomised, controlled, investigator-initiated and run, prospective, blinded, multicentre trial. Patients with recurrent autogenous arteriovenous haemodialysis fistula stenosis received standard endovascular treatment plus drug-eluting balloon or standard endovascular treatment plus uncoated balloon (Sham). Primary endpoint was late lumen loss in trial area on ultrasound at 6 weeks, 3, 6 and 12 months. Secondary endpoints were freedom from reintervention to the Index Trial Area and decline in fistula flow (Qa). Interim analysis was performed at 6 months (unblinded due to timeliness). Results: Patients with 132 recurrent stenoses (48% in bare Nitinol stents) were randomised with 70 receiving drug-eluting balloon and 62 Sham. At 6 months, decline in late lumen loss was 0.23 ± 0.03 mm/month for Sham and 0.045 ± 0.03 mm/month for drug-eluting balloon arm, a significant difference (0.18 mm, p = 0.0002). At 12 months, this difference persisted at 0.12 mm (p = 0.0003). At 6 months, significant difference in late lumen loss for instent restenoses (p = 0.0004) was observed, with non-significant difference for unstented restenoses (p = 0.065). Mean time for freedom from reintervention was 10.14 months for Sham versus 42.39 months for drug-eluting balloon (p = 0.001). The same was shown for instent (p = 0.014) and unstented (p = 0.029) restenoses. Qa decline rate at 6 months was 36.89 mL/min/month (Sham) and 0.41 mL/min (drug-eluting balloon). The difference was significant (36.48 mL/min; p = 0.02) and persisted to 12 months (p = 0.44). Conclusion: Paclitaxel drug-eluting balloon significantly delays restenosis after angioplasty for recurrent autogenous arteriovenous haemodialysis fistula stenosis, persisting to 12 months. Drug-eluting balloon significantly increases freedom from reintervention at 12 months with these effects true in stented and unstented fistulas.

Estilos ABNT, Harvard, Vancouver, APA, etc.

33

Chandrasekar, Baskaran, Martin Sirois, Pascale Geoffroy, Dominique Lauzier, Stanley Nattel e Jean-François Tanguay. "Local delivery of 17β-estradiol improves reendothelialization and decreases inflammation after coronary stenting in a porcine model". Thrombosis and Haemostasis 94, n.º 11 (2005): 1042–47. http://dx.doi.org/10.1160/th04-12-0823.

Texto completo da fonte

Resumo:

SummaryIn the current study, we investigated the effect of local intravascular delivery of 17β-estradiol (17β-E) on subsequent instent neointimal hyperplasia. Twenty-seven stents were implanted in coronary arteries of juvenile swine. Coronary arteries were randomized to local treatment with 17β-E or no drug therapy (control-vehicle treated). Twenty-eight days posttreatment, angiographic images revealed an improved minimal lumen diameter (2.2 ± 0.2 vs. 1.3 ± 0.2 mm, P < 0.005) and a reduction of late lumen loss (1.7 ± 0.2 vs. 2.3 ± 0.1 mm, P < 0.01) in 17β-E-treated vessels compared to control-vehicle treated. Histological analyses showed a reduction of stenosis (51.49 ± 6.75 vs.70.86 ± 6.24%, P < 0.05), mean neointimal thickness (0.51 ± 0.07 vs.0.83 ± 0.14 mm, P < 0.05) and inflammation score (1.29 ± 0.28 vs. 2.85 ± 0.40, P < 0.05) in 17β-E-treated arteries compared to control-vehicle treated arteries. Immunohistochemistry analyses revealed a reduction of proliferating smooth muscle cells and increased in-stent reendothelialization in 17β-E-treated arteries. Finally, we observed a correlation between neointimal hyperplasia and inflammation score, which in turn, was inversely related to reendothelialization. Locally delivered, 17β-E is inhibiting the inflammatory response and smooth muscle cells proliferation and improving vascular reendothelialization which together are contributing to reduce instent restenosis in a porcine coronary injury model. Together, these data demonstrate the potential clinical application of 17β-estradiol to improve vascular healing and prevent in-stent restenosis.

Estilos ABNT, Harvard, Vancouver, APA, etc.

34

Liang, Dongke, Da Zhi Yang, Min Qi e Wei Qiang Wang. "Finite Element Analysis of a Stent Implantation in a Stenosed Artery". Key Engineering Materials 288-289 (junho de 2005): 571–74. http://dx.doi.org/10.4028/www.scientific.net/kem.288-289.571.

Texto completo da fonte

Resumo:

Instent restenosis (ISR) has been a key factor that restricts the further use of intraoronary stents. And the mechanical interaction between the stent and the artery has been indicated as one of the significant causes for the activation of stent-related restenosis. However, there is very little quantitative information about the interaction of stent with artery. In order to improve the general understanding of coronary stenting, finite element method (FEM) has been used to model the revascularization of a stenosed artery through the insertion of a balloon-expandable stent. Given a stent design, the deformed shape of the stent and possible areas of the artery injury were presented. The fact that the distal end of stent penetrated into the artery wall may help to explain the phenomena that much restenosis occurs at the ends of stents. The recoil ratios of the stent model, the plaque-artery model and the stent-plaque-artery model were 2%, 26.7% and11.3%, respectively. They were well consistent with the experimental data. In conclusion, this work would be helpful for the general understanding of intraoronary stent implantation and stent design optimization.

Estilos ABNT, Harvard, Vancouver, APA, etc.

35

YIN, Yu-gang, e Bin WANG. "Effects of rosuvastatin on instent restenosis, plasma lipid level and inflammatory factors after coronary stenting". Academic Journal of Second Military Medical University 31, n.º 2 (31 de maio de 2011): 227–28. http://dx.doi.org/10.3724/sp.j.1008.2011.00227.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

36

Jayaraj, Arjun, e Seshadri Raju. "Utility of a Mechanical Thrombectomy Device in Treating Calcified Instent Restenosis Post Iliofemoral Venous Stenting". Annals of Vascular Surgery 79 (fevereiro de 2022): 443.e1–443.e5. http://dx.doi.org/10.1016/j.avsg.2021.08.020.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

37

Wei, X., Y. Zheng-Bai, S. Zhen-Qi e H. Hong-Hua. "Influence of the level of HB-EGF in serum on instent restenosis after CHD stenting". Heart 97, Suppl 3 (1 de outubro de 2011): A167. http://dx.doi.org/10.1136/heartjnl-2011-300867.495.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

38

Varenhorst, Christoph, Giovanna Sarno, Kristina Hambraeus, Oskar Angers, Gran Olivecrona, Bo Lagerqvist e Stefan James. "SCAAR: CHANGES IN DRUG ELUTING STENT USE AND INSTENT-RESTENOSIS RATES FROM 2002 TO 2012". Journal of the American College of Cardiology 63, n.º 12 (abril de 2014): A1902. http://dx.doi.org/10.1016/s0735-1097(14)61905-7.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

39

Chua, Dave C. Y., Francis Q. Almeda, Shaun Senter, Susie Kim, David S. Bromet, David Butzel, Cam Nguyen et al. "Visual assessment of procedural results following treatment with Sr-90 β-radiation for instent restenosis". Cardiovascular Radiation Medicine 3, n.º 3-4 (julho de 2002): 133–37. http://dx.doi.org/10.1016/s1522-1865(03)00102-1.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

40

Chua, Dave C. Y., Francis Q. Almeda, Shaun Senter, Justin Haynie, Cam Nguyen, James C. H. Chu, Clifford J. Kavinsky, R. Jeffrey Snell e Gary L. Schaer. "Predictors of late cardiac events following treatment with Sr-90 β-irradiation for instent restenosis". Cardiovascular Radiation Medicine 4, n.º 1 (janeiro de 2003): 7–11. http://dx.doi.org/10.1016/s1522-1865(03)00117-3.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

41

Lin, Chia-Chang, e Jun-Ting Liou. "TCTAP C-058 Severe BMS-Instent Restenosis Treated by Cutting & Drug-coated Balloon Dilatations". Journal of the American College of Cardiology 73, n.º 15 (abril de 2019): S128—S129. http://dx.doi.org/10.1016/j.jacc.2019.03.246.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

42

Montrivade, Sakolwat. "TCTAP C-083 Solving Recalcitrant Instent Restenosis With Combined Laser Atherectomy and Shockwave Intravascular Lithotripsy". Journal of the American College of Cardiology 83, n.º 16 (abril de 2024): S175—S177. http://dx.doi.org/10.1016/j.jacc.2024.03.190.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

43

Sadato, A., W. Taki, N. Sakai, T. Aoki, F. Isaka, H. Oowaki, T. Sato, Y. Kawanabe e N. Hashimoto. "Initial Experiences of Carotid Stenting with Palmaz Stent". Interventional Neuroradiology 5, n.º 1_suppl (novembro de 1999): 33–35. http://dx.doi.org/10.1177/15910199990050s105.

Texto completo da fonte

Resumo:

Results of cervical carotid stenting are reported. Twenty-nine lesions in 25 cases were treated by percutaneous transluminal balloon angioplasty combined with stent placement. All the lesions were successfully dilated. There was one embolic complication during the operation that caused deterioration of preoperative symptoms. Stent deformation causing more than 30% luminal narrowing occurred in one case. Instent restenosis with more than 50% luminal narrowing was seen in bilateral lesions in one case. These were satisfactory results as an initial experience, but further improvement in this technique is considered essential especially to avoid embolic complications.

Estilos ABNT, Harvard, Vancouver, APA, etc.

44

Zhou, Sheng-Nan, Le Yang, Bi-Yang Feng, Lei Liu e Li-Ming Chen. "In-Stent Restenosis: Achilles’ Heel of Post-PCI Era". Journal of Clinical Cardiology 5, n.º 1 (5 de janeiro de 2024): 1–5. http://dx.doi.org/10.33696/cardiology.5.047.

Texto completo da fonte

Resumo:

Despite advancements in stent design and polymer coatings over the past two decades, 1% to 2% of patients annually still experience instent restenosis (ISR). ISR reduces myocardial perfusion, may develop symptoms of myocardial ischemia, and thus leads to a high risk of myocardial infarction and cardiac death. Given that millions of drug-eluting stents (DES) are implanted globally every year, ISR remains a prevalent clinical issue with significant public health implications. Coronary intravascular imaging, includes intravascular ultrasound (IVUS) and optical coherence tomography (OCT), can help physicians gain deeper insights into the potential mechanisms of ISR. The preferred treatment strategy hinges on an accurate diagnosis and better understanding of etiology. The mechanism of ISR is multifaceted, and its treatment is challenging. Although the risk of ISR continues to decrease with advancements in DES application, further research is still needed to enrich the treatment options for ISR.

Estilos ABNT, Harvard, Vancouver, APA, etc.

45

Skoczyńska, Agnieszka, Andrzej Ochała, Sebastian Dworowy e Michał Tendera. "Drug eluting stent or drug eluting balloon? Which is the better device to treat instent restenosis?" Advances in Interventional Cardiology 2 (2011): 147–55. http://dx.doi.org/10.5114/pwki.2011.23167.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

46

Heck, D. "033 Incidence and time course of carotid instent restenosis in a consecutive series of 295 patients". Journal of NeuroInterventional Surgery 1, n.º 1 (1 de julho de 2009): 86–87. http://dx.doi.org/10.1136/jnis.2009.001016g.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

47

Fujiu, Katsuhito, Ichiro Manabe, Yumiko Oishi, Kensuke Tsushima, Go Nishimura e Ryozo Nagai. "ADMINISTRATION OF AM80 INHIBITED INSTENT RESTENOSIS BY MODULATING SMOOTH MUSCLE CELL PHENOTYPE IN VITRO AND VIVO". Cardiovascular Pathology 13, n.º 3 (maio de 2004): 159. http://dx.doi.org/10.1016/j.carpath.2004.03.480.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

48

Rittger, H., M. Waliszewski, J. Woehrle, C. Garlichs, C. Schlundt, J. Brachmann e S. Achenbach. "Prediction of therapy failure after treatment of instent-restenosis of drug-eluting stents with drug coated balloons". European Heart Journal 34, suppl 1 (2 de agosto de 2013): P4801. http://dx.doi.org/10.1093/eurheartj/eht310.p4801.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

49

Almeda, Francis Q., David Y. Chua, Sandeep Nathan, Susie Kim, Peter M. Meyer, Stephen T. Thew, Cam Nguyen et al. "Clinical outcomes of patients treated with the cutting balloon and Sr-90 β-irradiation for instent restenosis". Cardiovascular Radiation Medicine 3, n.º 1 (janeiro de 2002): 12–15. http://dx.doi.org/10.1016/s1522-1865(02)00146-4.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

50

Katsaros, K., W. Speidl, G. Zorn, K. Huber, G. Maurer, D. Glogar, J. Wojta e G. Christ. "ID: 65 PLASMINOGEN ACTIVATOR INHIBITOR-1 PLASMA LEVELS ARE ASSOCIATED WITH CORONARY INSTENT RESTENOSIS OF DRUG ELUTING STENTS". Journal of Thrombosis and Haemostasis 4, s1 (outubro de 2006): 161. http://dx.doi.org/10.1111/j.1538-7836.2006.00065.x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

Artigos de revistas sobre o tema "Instent restenosis"

Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos